Addex Therapeutics Ltd.ADXN
What Addex Therapeutics Ltd. does.
We are a clinical-stage pharmaceutical company focused on the development of a portfolio of novel orally available small molecule drug candidates. Our business comprises of a pipeline of proprietary clinical and preclinical stage drug candidates that are being developed by our partner and internally. We or our partner are developing these clinical and preclinical stage proprietary drug candidates for diseases for which there are no approved therapies or where improved therapies are needed including post-stroke sensorimotor recovery, traumatic brain injury, or TBI, recovery, substance use disorders, or, SUD, and chronic cough. We also hold a 20% equity interest in a spin out company, Neurosterix US Holdings LLC, a private company developing a portfolio of preclinical stage proprietary drug candidates for schizophrenia and mood disorders.
Our lead development compound is dipraglurant, a metabotropic glutamate receptor subtype 5 negative allosteric modulator, or mGlu5 NAM, currently under evaluation for future development in post-stroke/TBI recovery. On April 30, 2025, we announced entering into an option and collaboration agreement with Sinntaxis AB for an exclusive license to intellectual property covering the use of mGlu5 inhibitors for the treatment of brain injury recovery. The agreement also includes a research collaboration under which the Sinntaxis team will complete evaluation of dipraglurant for the treatment of brain injury recovery.
Revenue and profit, by fiscal year.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | $2.8M | $3.6M | $2.9M | $1.4M | $1.6M | $404,102 |
| Net income | -$14.8M | -$12.9M | -$15.4M | -$20.8M | -$10.6M | $7.1M |
| Free cash flow | -$9.5M | -$12.2M | -$14.7M | -$16.4M | -$8.0M | -$5.4M |
More on ADXN.
- Addex Therapeutics Ltd. summary
- Addex Therapeutics Ltd. financial statements
- Addex Therapeutics Ltd. key metrics
- Addex Therapeutics Ltd. health scores and style box
- Addex Therapeutics Ltd. earnings
- Addex Therapeutics Ltd. dividends
- Addex Therapeutics Ltd. valuation
- Addex Therapeutics Ltd. ownership and insiders
- Addex Therapeutics Ltd. peers
Figures from Addex Therapeutics Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.